Every 10-Q that Ultralife Corporation (ULBI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ULBI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ULBI filings page.
Ultralife Corporation reported Q2 2026 revenues of 47,943 (in thousands), slightly below 48,561 a year earlier, but expanded gross margin to 28.9% from 23.9%. Net income attributable to Ultralife rose to 2,543 (in thousands), or $0.15 per basic and diluted share.
Margin gains were driven by favorable product mix in both segments and a $1,102 IEEPA tariff refund recorded as a reduction of cost of products sold. Q2 adjusted EBITDA was 6,148 (in thousands). Backlog reached a record $117.5 million. Cash was 6,663 with 45,125 of term loan outstanding and no revolver borrowings. Management disclosed that a previously identified material weakness in internal control over financial reporting and related IT general controls remained under remediation as of June 30, 2026.
Ultralife Corporation reported a weaker first quarter of 2026, slipping into a small loss as revenue and margins declined. Revenue was $47,445, down 6.5% from $50,746 a year earlier, with both commercial and government/defense sales lower.
Gross margin fell to 21.3% from 25.1%, pressured by product mix, higher utility costs and one-time production disruptions. The company posted a net loss attributable to Ultralife of $451, or $0.03 per share, versus net income of $1,865, or $0.11 per share, last year.
Adjusted EBITDA was $3,209, or 6.8% of revenue, compared with $5,448, or 10.7%, reflecting lower volumes and higher operating expenses, including $847 of non-recurring consulting and litigation costs. Cash was $8,890 and the term loan balance was $48,188, with $2,256 of operating cash generated and debt covenants met. Management continues to remediate a previously disclosed material weakness in internal control over financial reporting.
Ultralife Corporation reported higher sales but lower profitability for the quarter ended September 30, 2025. Revenue rose to $43,371 from $35,694, driven mainly by Battery & Energy Products and the contribution from the October 2024 Electrochem acquisition. Gross margin slipped to 22.2% from 24.3%, reflecting less favorable product mix, component quality issues and lower factory throughput, leading to an operating loss of $951 and a net loss attributable to Ultralife of $1,220 versus net income of $258 a year earlier.
For the first nine months of 2025, revenue increased to $142,678 from $120,604, while net income attributable to Ultralife declined to $1,524 from $6,118, as higher interest expense and integration and restructuring costs weighed on results. Electrochem, acquired for $48,022 in cash, contributed nine‑month revenue of $23,718. To fund the deal, Ultralife entered a new credit agreement including a five‑year $55,000 term loan, with $50,937 outstanding at a 6.62% borrowing rate and all debt covenants met. Operating cash flow remained solid at $9,501, lifting cash to $9,260.